Shionogi &Shionogi & Co.,Ltd.4507東証プライム医薬品FY ending Mar 2024, consolidated, IFRS

Shionogi & FY ending Mar 2024 results

Shionogi & brought in ¥410.1B in revenue.

Revenue changed -3.9% from the prior year.

What changed from last year

FY ending Mar 2023 → FY ending Mar 2024

Sales and profit both slipped in FY ending Mar 2024.
Revenue went from ¥426.7B to ¥410.1B (-3.9%), and net income from ¥185B to ¥162B (-12.4%).
Even so, a 39.5% net margin means a large share of every sale still ends up as profit.
Cash from operations fell harder, to ¥154.3B (-13.3%).

Rival drugs or market shifts could cut sales of its HIV medicines and its antibiotics for drug-resistant infections.
If folding in Torii Pharmaceutical and JT's drug business runs late, the expected gains may not show up.
US drug-pricing rules could slow the edaravone business it bought from Tanabe Pharma.

Annual securities report / 事業等のリスク

FY ending Mar 2023 → FY ending Mar 2024

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Show source documents (3)

EDINET (FSA Japan)
訂正有価証券報告書－第161期(2025/04/01－2026/03/31)
ID S100Z43Z2026-09-25Open
EDINET (FSA Japan)
有価証券報告書－第158期(2022/04/01－2023/03/31)
ID S100R1052023-06-22Open
EDINET (FSA Japan)
有価証券報告書－第156期(令和2年4月1日－令和3年3月31日)
ID S100LMYP2021-06-23Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.